The application of global sensitivity analysis in the development of a physiologically based pharmacokinetic model for m-xylene and ethanol co-exposure in humans

被引:8
作者
Loizou, George D. [1 ]
McNally, Kevin [1 ]
Jones, Kate [1 ]
Cocker, John [1 ]
机构
[1] Hlth & Safety Lab, Math Sci Unit, Computat Toxicol Team, Buxton, Derby, England
关键词
PBPK modeling; xylene and ethanol coexposure; human volunteer study; global sensitivity analysis; kinetics; HEALTH-RISK ASSESSMENT; IN-VITRO DATA; PARTITION-COEFFICIENTS; HUMAN-POPULATIONS; PBPK MODELS; METABOLISM; EXPOSURE; TOLUENE; EXTRAPOLATION; SIMULATION;
D O I
10.3389/fphar.2015.00135
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Global sensitivity analysis (SA) was used during the development phase of a binary chemical physiologically based pharmacokinetic (PBPK) model used for the analysis of m-xylene and ethanol co-exposure in humans. SA was used to identify those parameters which had the most significant impact on variability of venous blood and exhaled m-xylene and urinary excretion of the major metabolite of m-xylene metabolism, 3-methyl hippuric acid. This analysis informed the selection of parameters for estimation/calibration by fitting to measured biological monitoring (BM) data in a Bayesian framework using Markov chain Monte Carlo (MCMC) simulation. Data generated in controlled human studies were shown to be useful for investigating the structure and quantitative outputs of PBPK models as well as the biological plausibility and variability of parameters for which measured values were not available. This approach ensured that a priori knowledge in the form of prior distributions was ascribed only to those parameters that were identified as having the greatest impact on variability. This is an efficient approach which helps reduce computational cost.
引用
收藏
页数:19
相关论文
共 57 条
[1]   Toxicokinetic modeling and its applications in chemical risk assessment [J].
Andersen, ME .
TOXICOLOGY LETTERS, 2003, 138 (1-2) :9-27
[2]   Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data:: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver [J].
Barter, Zoe E. ;
Bayliss, Martin K. ;
Beaune, Philip H. ;
Boobis, Alan R. ;
Carlile, David J. ;
Edwards, Robert J. ;
Houston, J. Brian ;
Lake, Brian G. ;
Lipscomb, John C. ;
Pelkonen, Olavi R. ;
Tucker, Geoffrey T. ;
Rostami-Hodjegan, Amin .
CURRENT DRUG METABOLISM, 2007, 8 (01) :33-45
[3]   Harmonization: Developing consistent guidelines for applying mode of action and dosimetry information to cancer and noncancer risk assessment [J].
Barton, HA ;
Andersen, ME ;
Clewell, HJ .
HUMAN AND ECOLOGICAL RISK ASSESSMENT, 1998, 4 (01) :75-115
[4]   Proper knowledge on toxicokinetics improves human hazard testing and subsequent health risk characterisation. A case study approach [J].
Bessems, Jos G. M. ;
Geraets, Liesbeth .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2013, 67 (03) :325-334
[5]   Physiological parameter values for physiologically based pharmacokinetic models [J].
Brown, RP ;
Delp, MD ;
Lindstedt, SL ;
Rhomberg, LR ;
Beliles, RP .
TOXICOLOGY AND INDUSTRIAL HEALTH, 1997, 13 (04) :407-484
[6]   Use of mode of action in risk assessment: Past, present, and future [J].
Clewell, H .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2005, 42 (01) :3-14
[7]  
Clewell H J 3rd, 1985, Toxicol Ind Health, V1, P111
[8]   THE APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING IN HUMAN HEALTH RISK ASSESSMENT OF HAZARDOUS SUBSTANCES [J].
CLEWELL, HJ .
TOXICOLOGY LETTERS, 1995, 79 (1-3) :207-217
[9]   Use of physiologically based pharmacokinetic modeling to investigate individual versus population risk [J].
Clewell, HJ ;
Andersen, ME .
TOXICOLOGY, 1996, 111 (1-3) :315-329
[10]  
CLEWELL HJ, 1987, DRINKING WATER HLTH, V8, P159